CARIS LIFE SCIENCES, INC. Increase (Decrease) in Accrued Liabilities
CARIS LIFE SCIENCES, INC. (CAI) reported Increase (Decrease) in Accrued Liabilities of $10.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-05
- CARIS LIFE SCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $25.08M.
- CARIS LIFE SCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$14.98M, a 680.50% decline year-over-year.
- CARIS LIFE SCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $29.27M, a 97.46% increase year-over-year.
- CARIS LIFE SCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $889.00K.
- CARIS LIFE SCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $11.48M, a 1329.51% increase from fiscal 2024.
- CARIS LIFE SCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $803.00K, a 36.27% decline from fiscal 2023.
- CARIS LIFE SCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $1.26M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.10M 10-Q · filed 2026-08-05 | $39.37M derived: sum of 3 quarters · filed 2026-08-05 | $40.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$14.98M 10-Q · filed 2026-05-08 | $14.29M derived: sum of 2 quarters · filed 2026-05-08 | $15.18M derived: sum of 3 quarters · filed 2026-05-08 | -$6.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $29.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $30.16M derived: sum of 2 quarters · filed 2026-03-03 | $8.90M derived: sum of 3 quarters · filed 2026-08-05 | $11.48M 10-K · filed 2026-03-03 |
| 2025-09-30 | $889.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$20.37M derived: sum of 2 quarters · filed 2026-08-05 | -$17.79M 10-Q · filed 2025-11-05 | -$2.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$21.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$18.68M 10-Q · filed 2026-08-05 | -$3.86M derived: sum of 3 quarters · filed 2026-08-05 | -$20.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.58M 10-Q · filed 2026-05-08 | $17.40M derived: sum of 2 quarters · filed 2026-05-08 | $954.00K derived: sum of 3 quarters · filed 2026-05-08 | |
| 2024-12-31 | $14.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$1.63M derived: sum of 2 quarters · filed 2026-03-03 | $803.00K 10-K · filed 2026-03-03 | |
| 2024-09-30 | -$16.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$14.02M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $2.43M 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | $1.26M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |